With a truly patient-focussed approach we offer a best-in-class Early Access Program service that ensures patient, healthcare professional, and client needs are met through passionate and tailored program delivery.
Sourcing commercial drug products for clinical trials can be a complex process and is often one of the last considerations during study design. Our experienced Global Sourcing Team is uniquely positioned to support you through the commercial drug sourcing process with their deep understanding of clinical trials and commercial drug markets.
Download here
Bionical Emas, a global Contract Research Organisation (CRO) providing services to the pharmaceutical and biotech sectors, has appointed Tom Watson as its Chief Executive Officer (CEO). Jonathan Waring-Hughes has left the business.
Tom joined Bionical Emas four years ago. For the last year, he has been on Bionical Emas’ board as Chief Operating Officer (COO). Before that, he led the Group’s rapidly growing Early Access Programs (EAP) business.
“We are delighted to appoint Tom as Chief Executive Officer. He has operated across the international clinical research and services sector for many years and brings considerable experience and expertise.
The Board looks forward to supporting the business to continue to go from strength to strength over the coming years.”
-Andrew Borkowski, Chairman at Bionical Emas
Bionical Emas Katie Clayton Vice President Marketing +44 (0) 1462 416435
Bionical Emas is a Contract Research Organisation (CRO) which combines Clinical Development, Early Access Program (EAP) and Clinical Trial Supply (CTS) services to deliver a unique, seamless approach to pioneering the way life-changing medicines are developed and accessed for patients around the world.
The Group deliver full clinical development services to global pharma and biotech companies. It’s integrated suite of services enables Bionical Emas to maximize access, collect data and generate evidence at every point along the drug development pathway.
Bionical Emas runs global programs, employs 250 people, and has offices in US, Europe, and Australia. It serves 10 of the top 25 pharma companies.
